Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Shield Therapeutics ( (GB:STX) ) is now available.
Shield Therapeutics has announced that the FDA has accepted ACCRUFeR®/FeRACCRU® for Priority Review to extend its indication to adolescents with iron deficiency anemia, with approval anticipated in 2026. This development follows successful Phase 3 trials and could significantly expand the patient base, offering a novel oral treatment option for both adolescents and potentially adults who have difficulty swallowing capsules.
The most recent analyst rating on (GB:STX) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Spark’s Take on GB:STX Stock
According to Spark, TipRanks’ AI Analyst, GB:STX is a Neutral.
The overall stock score is primarily influenced by the company’s robust technical performance, indicating strong market momentum. However, significant financial weaknesses, including negative profitability and cash flow issues, weigh heavily on the score. Valuation concerns due to a negative P/E ratio and lack of dividend yield further impact the stock’s attractiveness.
To see Spark’s full report on GB:STX stock, click here.
More about Shield Therapeutics
Shield Therapeutics plc is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency with or without anemia through its innovative product, ACCRUFeR®/FeRACCRU® (ferric maltol). The company has launched ACCRUFeR® in the U.S. in collaboration with Viatris and has licensed its rights to several pharmaceutical companies globally, including in Europe, China, and Japan.
Average Trading Volume: 2,804,225
Technical Sentiment Signal: Hold
Current Market Cap: £70.83M
For an in-depth examination of STX stock, go to TipRanks’ Overview page.